Spring 2017

Which Leads to Higher Medication Substitution Treatment Retention – Methadone or Buprenorphine?: A Systematic Literature Review

Magalloway Field  
University of Southern Maine

Amy Rowe  
University of Southern Maine

Follow this and additional works at: http://digitalcommons.usm.maine.edu/thinking_matters

Part of the Nursing Commons

Recommended Citation
Field, Magalloway and Rowe, Amy, "Which Leads to Higher Medication Substitution Treatment Retention – Methadone or Buprenorphine?: A Systematic Literature Review" (2017). Thinking Matters. 111.  
http://digitalcommons.usm.maine.edu/thinking_matters/111

This Poster Session is brought to you for free and open access by the Student Scholarship at USM Digital Commons. It has been accepted for inclusion in Thinking Matters by an authorized administrator of USM Digital Commons. For more information, please contact jessica.c.hovey@maine.edu.
Which Leads to Higher Medication Substitution Treatment Retention – Methadone or Buprenorphine?:
A Systematic Literature Review

Magalloway Field BSN, RN, Amy Rowe BA, BSN, RN
Graduate Nursing Students
University of Southern Maine School of Nursing April, 2017

Introduction

The opioid epidemic in the United States is worsening; in fact, the number of drug overdoses almost tripled in the U.S. from 1999-2014 (Rudd, Seth, David, & Scholl, 2016). In 2015 alone, there were 52,404 drug overdose deaths, with 33,091 (63.9%) involving opioids (Rudd et al., 2016). From 2010-2015, death rates increased in thirty states and remained stable in nineteen (Rudd et al., 2016). Clausen, Waal, Thoresen, and Gossop (2009) report that mortality rates among opioid users are six to thirty times higher than those of populations in the same age- and gender-bracket of non-users. Clearly opioid addiction is a public health problem. It is associated with several risks in addition to overdose-related deaths, including intravenous drug administration, homelessness, and polysubstance use (Dunn et al., 2013). Actually, secondary to intravenous drug use, the proportion of Hepatitis C-positive opioid users increased from 21% to 75% in a five-year period, thus leading to a rise in Hepatitis C-related complications in this population (Dunn et al., 2013). There are several, multifaceted efforts that need to be made to help reduce opioid addiction, including extending opioid use treatment programs. In particular, medication-assisted treatment (MST) programs with methadone or buprenorphine should be emphasized. Future research is needed to determine whether methadone or buprenorphine treatment programs yield greater retention rates. The purpose of this literature review is to review and report on the relationship between type of medication-assisted treatment for opioid addiction and treatment retention.

Methods

Databases searched with keywords, inclusion and exclusion criteria applied
83 duplicates removed
N = 390
Screened by titles and abstracts
N = 307
Full-text articles assessed for eligibility
N = 71
N = 8

Data Bases Searched: Medline and CINAHL

Keywords Used: methadone, buprenorphine, treatment, and retention

Inclusion criteria: comparison studies between methadone and buprenorphine, outcome variable of treatment retention of six months or longer, studies published in English between 2009 and 2016

Exclusion criteria: studies examining pregnant women, neonates, naloxone, and not both methadone and buprenorphine were excluded

References (Full reference list available upon request)


Discussion

The literature overwhelmingly supported the use of methadone over buprenorphine regarding treatment retention, with methadone treatment programs retaining patients nearly 50% more than buprenorphine. In addition, patients on buprenorphine are more likely to have multiple treatment episodes and switch medications. However, buprenorphine shows more promise in helping patients abstain from illicit drug use. This has implications for practice, future research, education, and policy. Future research is needed to identify interventions to reduce early treatment cessation for buprenorphine patients. These interventions could include further training and education for providers in proper prescription of buprenorphine treatment to reduce withdrawal symptoms and early drop-out. Implications for practice are numerous and include receiving education and being aware that buprenorphine patients are at a higher risk of experiencing withdrawal symptoms. Policy work should focus on standardizing training and education among all MST prescribers. Literature suggests training should include mandatory addiction education in graduate school and through medical associations (Nosyck, Anglin, Brissette et al., 2013). Specific implications for nursing include the need for education regarding MST programs and appropriate medication dosing interventions to help reduce withdrawal symptoms, and the need to advocate for these patients at the policy level. Limitations of this study include limited time, lack of applicable studies on this topic, and novice researchers.